← Browse by Condition
Medical Condition
urothelial carcinoma
Total Trials
14
Recruiting Now
14
Trial Phases
Phase 1, Phase 2
ClinicalMetric tracks all active clinical trials for urothelial carcinoma sourced from ClinicalTrials.gov. Each listing includes the NCT identifier, current recruitment status, phase, primary endpoints, sponsor, estimated enrollment, and participating countries — updated daily as new studies open and status changes.
- Recruiting trials currently enrolling participants, with eligibility criteria and age requirements
- Phase 1–4 studies from early safety trials to post-marketing surveillance
- NIH, pharmaceutical sponsor, and academic medical center studies worldwide
- AI-powered plain-language summary available for every trial listing
Frequently Asked Questions — urothelial carcinoma Clinical Trials
How many clinical trials are currently recruiting for urothelial carcinoma?
ClinicalMetric currently tracks 14 actively recruiting clinical trials for urothelial carcinoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 14. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for urothelial carcinoma?
urothelial carcinoma research spans Phase 1 (3 trials), Phase 2 (5 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a urothelial carcinoma clinical trial?
Eligibility criteria for urothelial carcinoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1 3
Phase 2 5
Top Sponsors
2 trials
1 trial
1 trial
1 trial
1 trial
Recruiting Clinical Trials
NCT05646485
Recruiting
Bladder Cancer Screening Trial
Enrollment
1,000 pts
Location
United States
Sponsor
University of Texas Southweste...
NCT06026189
Recruiting
Safely Reduce Cystoscopic Evaluations for Hematuria Patients
Enrollment
1,100 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
NCT06451497 Phase 1
Recruiting
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Enrollment
100 pts
Location
United States
Sponsor
Zumutor Biologics Inc.
NCT07043972 Phase 2
Recruiting
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma
Enrollment
55 pts
Location
United States
Sponsor
Fox Chase Cancer Center
NCT06262516
Recruiting
Nephroureterectomy With and Without Lymph Node Dissection for Upper Tract Urothelial Cell Carcinoma
Enrollment
94 pts
Location
United States
Sponsor
Case Comprehensive Cancer Cent...
NCT06617169 Phase 1
Recruiting
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
Enrollment
12 pts
Location
Australia
Sponsor
Monopar Therapeutics
NCT07118176 Phase 1
Recruiting
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Enrollment
30 pts
Location
United States
Sponsor
Jonsson Comprehensive Cancer C...
NCT06120374
Recruiting
Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC
Enrollment
178 pts
Location
China
Sponsor
Peking University First Hospit...
NCT06823427 Phase 2
Recruiting
9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma
Enrollment
60 pts
Location
China
Sponsor
Mabwell (Shanghai) Bioscience ...
NCT06683846 Phase 2
Recruiting
Ivonescimab in the Treatment of Multiple Advanced Tumors
Enrollment
400 pts
Location
China
Sponsor
Fudan University
NCT05600127 Phase 2
Recruiting
Chemotherapy and Sequential Immunotherapy for Locally Advanced Urothelial Cancer
Enrollment
64 pts
Location
Netherlands
Sponsor
Erasmus Medical Center
NCT05239624 Phase 2
Recruiting
Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Enrollment
23 pts
Location
United States
Sponsor
Memorial Sloan Kettering Cance...
NCT06101290
Recruiting
Locally Ablative TherapY in Oligo-ProgressiVe GEnitourinary TumoRs (LAYOVER)
Enrollment
150 pts
Location
United States
Sponsor
University of California, Davi...
NCT03452774
Recruiting
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Enrollment
50,000 pts
Location
United States, Puert...
Sponsor
Massive Bio, Inc.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology